• Je něco špatně v tomto záznamu ?

Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab

M. Svaton, M. Knetki-Wroblewska, S. Tabor, P. Domecky, O. Venclicek, J. Krejci, M. Drosslerova, M. Hrnciarik, D. Hricisak, A. Bejckova, O. Fischer, M. Vitkova, M. Krzakowski

. 2024 ; 38 (5) : 2434-2440. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019054

BACKGROUND/AIM: Cemiplimab in patients with non-small cell lung cancer (NSCLC) with PD-L1 (programmed death ligand type 1) expression ≥50% showed a significant improved overall survival (OS) with increasing expression of PD-L1. To our knowledge there exist no similar data published for pembrolizumab regarding the increased OS in relation to the PD-L1 expression. Therefore, the objective of our study was to determine whether improvement in OS reflects increased expression levels of PD-L1 (≥50%) in patients with NSCLC. PATIENTS AND METHODS: Retrospective data from 9 Czech and 1 Polish comprehensive oncology Centers were used. All patients with stage IV NSCLC and PD-L1 expression ≥50% treated with pembrolizumab in daily practice were included. The groups of patients according to the expression of PD-L1 were determined as follows: PD-L1 50-59%, 60-69%, 70-79%, 80-89% and 90-100%. The log-rank test and the Cox regression model were used to compare survival between study groups. RESULTS: A total of 617 patients were included in the study. We did not observe a statistically significant difference in OS between groups of patients with different levels of PD-L1 expression in the pooled comparison (p=0.445). Furthermore, we did not observe a statistically significant difference even when comparing OS in patients with PD-L1expression of 50-59% (reference) with the group of other patients according to the level of expression of PD-L1 in the Cox regression model including the effect covariates. CONCLUSION: PD-L1 expression showed no significant effect on OS in patients with NSCLC with PD-L1≥50% treated with pembrolizumab.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019054
003      
CZ-PrNML
005      
20241024111612.0
007      
ta
008      
241015s2024 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.13712 $2 doi
035    __
$a (PubMed)39187353
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Svaton, Martin $u Department of Pneumology and Phthiseology, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; svatonm@fnplzen.cz
245    10
$a Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab / $c M. Svaton, M. Knetki-Wroblewska, S. Tabor, P. Domecky, O. Venclicek, J. Krejci, M. Drosslerova, M. Hrnciarik, D. Hricisak, A. Bejckova, O. Fischer, M. Vitkova, M. Krzakowski
520    9_
$a BACKGROUND/AIM: Cemiplimab in patients with non-small cell lung cancer (NSCLC) with PD-L1 (programmed death ligand type 1) expression ≥50% showed a significant improved overall survival (OS) with increasing expression of PD-L1. To our knowledge there exist no similar data published for pembrolizumab regarding the increased OS in relation to the PD-L1 expression. Therefore, the objective of our study was to determine whether improvement in OS reflects increased expression levels of PD-L1 (≥50%) in patients with NSCLC. PATIENTS AND METHODS: Retrospective data from 9 Czech and 1 Polish comprehensive oncology Centers were used. All patients with stage IV NSCLC and PD-L1 expression ≥50% treated with pembrolizumab in daily practice were included. The groups of patients according to the expression of PD-L1 were determined as follows: PD-L1 50-59%, 60-69%, 70-79%, 80-89% and 90-100%. The log-rank test and the Cox regression model were used to compare survival between study groups. RESULTS: A total of 617 patients were included in the study. We did not observe a statistically significant difference in OS between groups of patients with different levels of PD-L1 expression in the pooled comparison (p=0.445). Furthermore, we did not observe a statistically significant difference even when comparing OS in patients with PD-L1expression of 50-59% (reference) with the group of other patients according to the level of expression of PD-L1 in the Cox regression model including the effect covariates. CONCLUSION: PD-L1 expression showed no significant effect on OS in patients with NSCLC with PD-L1≥50% treated with pembrolizumab.
650    _2
$a lidé $7 D006801
650    12
$a nemalobuněčný karcinom plic $x farmakoterapie $x mortalita $x metabolismus $x patologie $x genetika $7 D002289
650    12
$a antigeny CD274 $x metabolismus $x genetika $7 D060890
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory plic $x farmakoterapie $x mortalita $x metabolismus $x patologie $x genetika $7 D008175
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a dospělí $7 D000328
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Knetki-Wroblewska, Magdalena $u Department of Lung Cancer and Chest Tumours Maria Sklodowska-Curie National Research Institute of Cancer, Warsaw, Poland
700    1_
$a Tabor, Sylwia $u Department of Lung Cancer and Chest Tumours Maria Sklodowska-Curie National Research Institute of Cancer, Warsaw, Poland
700    1_
$a Domecky, Petr $u OAKS Consulting s.r.o., Prague, Czech Republic $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Venclicek, Ondrej $u Department of Respiratory Diseases, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Krejci, Jana $u Department of Pneumology, Bulovka Hospital, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Drosslerova, Marie $u Department of Respiratory Medicine, Thomayer Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hrnciarik, Michal $u Pulmonary Department, University Hospital Hradec Kralove, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Hricisak, Daniel $u Department of Oncology, Liberec Regional Hospital, Liberec, Czech Republic
700    1_
$a Bejckova, Alzbeta $u Department of Pulmonology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Fischer, Ondrej $u Department of Respiratory Medicine, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Vitkova, Martina $u Multiscan Pardubice Oncology Centre, Pardubice Hospital, Pardubice, Czech Republic
700    1_
$a Krzakowski, Maciej $u Department of Lung Cancer and Chest Tumours Maria Sklodowska-Curie National Research Institute of Cancer, Warsaw, Poland
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 38, č. 5 (2024), s. 2434-2440
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39187353 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111606 $b ABA008
999    __
$a ok $b bmc $g 2201712 $s 1231027
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 38 $c 5 $d 2434-2440 $e - $i 1791-7549 $m In vivo (Athens, Greece) $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace